Clinical Trial

AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer

Name: AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer — clinical trial record (NCT07712094)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is a single prospective, parallel, double-cohort, multicenter phase II clinical trial, aiming to evaluate the efficacy and safety of ivonescimab (AK112) combined with IP chemotherapy ± TACE in the first-line treatment of metastatic digestive system neuroendocrine cancer.

Trial Details

NCT Number	NCT07712094
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Neuroendocrine Cancer
Enrollment	56 participants
Start Date	2026-08-01
Primary Completion	2029-02-27 (estimated)
Study Completion	2029-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-17